Class I histone deacetylase (HDAC) inhibitor (IC50 values are 150, 370, 760 and 5000 nM for HDAC1, HDAC3, HDAC2 and HDAC8 respectively). Exhibits slow, tight-binding inhibitory activity. Displays no activity against class II HDACs. Brain penetrant.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 339.43. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.95 mL||14.73 mL||29.46 mL|
|5 mM||0.59 mL||2.95 mL||5.89 mL|
|10 mM||0.29 mL||1.47 mL||2.95 mL|
|50 mM||0.06 mL||0.29 mL||0.59 mL|
References are publications that support the biological activity of the product.
Chou et al (2008) Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J.Biol.Chem. 283 35402 PMID: 18953021
Rai et al (2008) HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3 e1958 PMID: 18463734
Xu et al (2009) Chemical probes identify a role for histone deacetylase 3 in Friedrich's ataxia gene silencing. Chem.Biol. 16 980 PMID: 19778726
If you know of a relevant reference for TC-H 106, please let us know.
View Related Products by Product Action
Keywords: TC-H 106, TC-H 106 supplier, TC-H106, histones, deacetylases, hdacs, inhibitiors, class, I, HDAC3, HDAC1, epigenetics, Class, HDACs, 4270, Tocris Bioscience
Citations for TC-H 106
Citations are publications that use Tocris products.
Currently there are no citations for TC-H 106. Do you know of a great paper that uses TC-H 106 from Tocris? Please let us know.
Reviews for TC-H 106
There are currently no reviews for this product. Be the first to review TC-H 106 and earn rewards!
Have you used TC-H 106?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Cell Cycle & DNA Damage Repair Poster
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
Epigenetics in Cancer Poster
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.